Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
In stage A, the primary objective is: - To compare the relative bioavailability of a single dose of 300 mg LX6171 using a 40mg/mL and an 80mg/mL formulated suspension; - To evaluate plasma concentrations of LX6171 and its major metabolite LP-523122 after a single 300 mg administration of LX6171 oral suspension at two concentrations (40 mg/mL and 80 mg/mL), in order to determine doses to be utilized over a 28 day period (see stage B). In stage B, the primary objective is: - To evaluate the safety and tolerability of 2 dose levels LX6171 oral suspension when administered for 28 days, in subjects exhibiting AAMI
Critère d'inclusion
- Age-Associated Memory Impairment (AAMI)